Toronto-based BenchSci, which uses AI to help pharmaceutical firms accelerate drug discovery, raised a CA$95M Series D led by Generation Investment Management
Context & Ripple Effects
BenchSci has now scaled from the $22M Series B it raised in early 2020 to a CA$95M Series D led by Generation Investment Management — a four-year climb that keeps the company on the same funding trajectory Benchling rode through four rounds to become the benchmark for biotech R&D software valuations.
The round lands amid a visible Toronto cluster forming around AI for pharma: weeks earlier, ODAIA raised a $25M Series B for software helping pharmaceutical firms bring drugs to market, giving the city funded players on both the discovery and commercialization ends of the pipeline.
First-order effects
- BenchSci gets late-stage capital to expand its AI platform for interpreting scientific experiments at pharma customers, while Generation Investment Management takes a lead position in drug-discovery software rather than therapeutics itself.
- Pharma buyers now face two well-funded Canadian vendors — BenchSci in discovery and ODAIA in go-to-market — pitching adjacent slices of the same drug-development workflow.
Second-order effects
- Benchling's run of mega-rounds set the valuation template for lab-facing software, so BenchSci's Series D pricing will be measured against that bar and pressures other R&D-software vendors to raise or differentiate before the category consolidates.
- A sustainability-oriented lead investor backing an AI tool that cuts failed experiments gives pharma CIOs an efficiency-and-ESG story when justifying spend on discovery software.
Third-order effects
- If the pattern holds, drug development becomes layered with specialized AI vendors — experiment data, discovery hypotheses, commercialization — each raising separately, pushing pharma toward integration decisions about whether to buy point solutions or demand consolidated platforms.
The trend: AI-for-pharma is attracting dedicated growth capital round by round, with Toronto emerging as a hub for tools covering the drug pipeline end to end.